Expert Insights
ETF Channels
ETF Strategist
Exchange – An ETF Experience
Multi-Asset
Smart Beta
Beyond Basic Beta
Thematic Investing
Leveraged & Inverse
Disruptive Technology
Innovative ETFs
Equity ETF
Retirement ETF
Crypto
ETF Building Blocks
Nasdaq Investment Intelligence
Model Portfolio
Active ETF
ESG
Multi-Factor
Entrepreneur ETF
ETF 360
ETF Education
Gold & Silver Investing
Webcasts
Popular ETFs
SPY – SPDR S&P 500 ETF
VOO – Vanguard S&P 500 ETF
QQQ – Invesco QQQ ETF
GLD – SPDR Gold Shares ETF
IVV – iShares Core S&P 500 ETF
EFA – iShares MSCI EAFE ETF
EEM – iShares MSCI Emerging Markets ETF
IEMG – iShares Core MSCI Emerging Markets ETF
VTI – Vanguard Total Stock Market ETF
GDX – VanEck Vectors Gold Miners ETF
XLF – Financial Select Sector SPDR Fund
VEA – Vanguard FTSE Developed Markets ETF
VTV – Vanguard Value ETF
Top Gold ETFs
Top Oil ETFs
Top Commodity ETFs
Top Hedge Fund ETFs
Top Financials ETFs
Top Inverse Equities ETFs
Top High Yield Bond ETFs
ETF Education
Newsletter
New ETFs
ETF Ecosystem
Education Central
Video
Podcasts
ETF Playbook
Virtual Summits
ETFs Future-Forward 2021: An iShares Investing Symposium
Three Themes for 2021: An iShares & MSCI Investing Symposium
Salix
Featured
Salix Bidding War Provides Modest Boost for Pharma ETFs
By
Todd Shriber
March 11, 2015
X
